Phase 3 Licensing Deal Benchmarks

Phase 3 licensing deals represent the most de-risked and highest-value segment of biopharma transactions. Median total deal values at Phase 3 reach $3.1B, with upfront payments between $472M and $1.0B. The substantial upfronts reflect the near-term revenue potential and reduced regulatory risk of pivotal-stage assets.

Phase 3 deal structures shift toward higher upfront allocations, with a recommended 23/77 upfront/milestone split. Development milestones are more focused at $243M, covering Phase 3 completion and NDA/BLA filing. Regulatory milestones ($849M) and commercial milestones ($1.3B) make up the remainder.

Royalty rates at Phase 3 command premium levels of 16.1%-24.6%, with high-tier escalation to 28.6%. The reduced risk profile justifies higher fixed royalty commitments for licensees. Assets with strong Phase 3 interim data or breakthrough therapy designation can command even higher terms.